# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NR improved the six-minute walking distance and treadmill walking time for those with PAD
Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.